CardiologyCommons

professional and social network for cardiology

All Blog Posts (7)

Losartan TREATMENT HF

Reascher:In my opinion, at this time Losartan 150 mg is much better than 50 mg in terms of the edendpoints. There is a 10% decrease with 150 mg of Losartan in terms of reducing death or heart failure hospitalization. The HEAALstudy is the first to verify that 150 mg of Losartan has a therapeutic effect in the treatment of heart failure. Also, in Chinathe first time RAS blockade used to treat heart failure were ACE inhibitors but we have about 20% of patients with coughafter…

Continue

Added by min zhao on March 9, 2011 at 8:00pm — No Comments

ABOUT HF

Reascher:I’d like to talk today about heart failure specifically. We have seen several lead breaking heart failure trials presented here at AHA 2009 and one of those trials was the HEAAL study. Can you give us your brief opinion on the HEAAL study as well as any comments about how we can evaluate it? Additionally, what do you think the contribution is to the progress regarding how we can treat heart failure?

 Prof. Nissen:We don’t use Losartan very…

Continue

Added by min zhao on March 9, 2011 at 8:00pm — 1 Comment

What about in those patients with AF?

Reascher:What about in those patients with AF?

 

Prof. Jessup : Physicians often times use the wrong drugs to slow heart rate or they may combine a calcium antagonist drug in someone who has a poor ejection fraction and that is the wrong thing to do. I think that the guidelines that came out today are very helpful.

Added by min zhao on March 9, 2011 at 7:59pm — 1 Comment

What is the most efficient or best way to screen out patients who are at high risk for heart failure?

Reascher:What is the most efficient or best way to screen out patients who are at high risk for heart failure?

 

Prof. Jessup : In general physicians do understand who is at high risk. High-risk patients include patients in the hospital frequently, those with an elevated BUN and creatinine, patients with low blood pressure, or multiple comorbidities, which this session was about. Most physicians will understand those patients to be high risk but do not necessarily act on that…

Continue

Added by min zhao on March 9, 2011 at 7:57pm — No Comments

using beta-blockers in heart failure?

Reascher:What are some key issues when using beta-blockers in heart failure?

 

Prof. Jessup : The data still says that physicians are not increasing the beta-blockers to their target level. It is easy to keep patients on a very low dose and we all must continue to try to push up the doses of beta-blockers and use evidence-based beta-blockers.

Added by min zhao on March 9, 2011 at 7:55pm — No Comments

two different types of devices

Research:Research and application of continuous-flow ventricular assist devices is increasing and recent data reported superiority of these devices to pulsatile assist devices to some extent. What is your view of the merits of these two different types of devices?

Prof. Jessup : The advantages of the non-pulsatile VADs are that they have a smaller imprint so the surgery to implant them is better tolerated and they also accordingly have a decreased infection rate. The original fear was…

Continue

Added by min zhao on March 9, 2011 at 7:52pm — No Comments

ECHO BOARDS PREPARATION

I just took the echo boards this past month. It is definitely one of the more challenging board exams, and definitely requires thorough study and preparation to pass.

I felt overall the test was reasonable and fair. There were a few questions here and there on minutiae and esoteric stuff, but not excessive. You definitely have to know some physics for the exam.

Here are some of the study sources my colleagues and I used:

1) Textbooks: A) Jae K. Oh (Echo…

Continue

Added by WC on November 1, 2010 at 5:53pm — No Comments

© 2017   Created by CardiologyCommons Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service